No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
rituximab + lenalidomide Sensitive: A1 - Approval
FDA - 5 days (NewA1)
|
rituximab + lenalidomide Sensitive: A1 - Approval
FDA - 5 days - (New A1)
|
TNFAIP3 mutation
|
Marginal Zone Lymphoma
|
TNFAIP3 mutation
|
Marginal Zone Lymphoma
|
zanubrutinib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
zanubrutinib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
MYD88 mutation
|
Marginal Zone Lymphoma
|
MYD88 mutation
|
Marginal Zone Lymphoma
|
zanubrutinib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
zanubrutinib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
zanubrutinib Sensitive: A1 - Approval
|
zanubrutinib Sensitive: A1 - Approval
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
umbralisib Sensitive: A1 - Approval
|
umbralisib Sensitive: A1 - Approval
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
ibrutinib Sensitive: A1 - Approval
|
ibrutinib Sensitive: A1 - Approval
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
R-CVP Sensitive: A2 - Guideline
|
R-CVP Sensitive: A2 - Guideline
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
R-CHOP Sensitive: A2 - Guideline
|
R-CHOP Sensitive: A2 - Guideline
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
rituximab Sensitive: A2 - Guideline
|
rituximab Sensitive: A2 - Guideline
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
axicabtagene ciloleucel Sensitive: A2 - Guideline
|
axicabtagene ciloleucel Sensitive: A2 - Guideline
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
obinutuzumab Sensitive: A2 - Guideline
|
obinutuzumab Sensitive: A2 - Guideline
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
idelalisib Sensitive: A2 - Guideline
|
idelalisib Sensitive: A2 - Guideline
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
duvelisib Sensitive: A2 - Guideline
|
duvelisib Sensitive: A2 - Guideline
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
copanlisib Sensitive: A2 - Guideline
|
copanlisib Sensitive: A2 - Guideline
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
cyclophosphamide Sensitive: A2 - Guideline
|
cyclophosphamide Sensitive: A2 - Guideline
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
chlorambucil Sensitive: A2 - Guideline
|
chlorambucil Sensitive: A2 - Guideline
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
ibritumomab tiuxetan Sensitive: A2 - Guideline
|
ibritumomab tiuxetan Sensitive: A2 - Guideline
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
G-CHOP Sensitive: A2 - Guideline
|
G-CHOP Sensitive: A2 - Guideline
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
lisocabtagene maraleucel Sensitive: A2 - Guideline
|
lisocabtagene maraleucel Sensitive: A2 - Guideline
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
tisagenlecleucel-T Sensitive: A2 - Guideline
|
tisagenlecleucel-T Sensitive: A2 - Guideline
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
O-CVP Sensitive: A2 - Guideline
|
O-CVP Sensitive: A2 - Guideline
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
INCB50465 Sensitive: B - Late Trials
|
INCB50465 Sensitive: B - Late Trials
|
MYD88 mutation
|
Marginal Zone Lymphoma
|
MYD88 mutation
|
Marginal Zone Lymphoma
|
ibrutinib Sensitive: C3 – Early Trials
|
ibrutinib Sensitive: C3 – Early Trials
|
CARD11 mutation
|
Marginal Zone Lymphoma
|
CARD11 mutation
|
Marginal Zone Lymphoma
|
ibrutinib Resistant: C3 – Early Trials
|
ibrutinib Resistant: C3 – Early Trials
|
KMT2D mutation
|
Marginal Zone Lymphoma
|
KMT2D mutation
|
Marginal Zone Lymphoma
|
ibrutinib Resistant: C3 – Early Trials
|
ibrutinib Resistant: C3 – Early Trials
|
MYD88 L265P
|
Marginal Zone Lymphoma
|
MYD88 L265P
|
Marginal Zone Lymphoma
|
ibrutinib Sensitive: C3 – Early Trials
|
ibrutinib Sensitive: C3 – Early Trials
|
TNFAIP3 mutation
|
Marginal Zone Lymphoma
|
TNFAIP3 mutation
|
Marginal Zone Lymphoma
|
ibrutinib Sensitive: C3 – Early Trials
|
ibrutinib Sensitive: C3 – Early Trials
|
CD5 positive
|
Marginal Zone Lymphoma
|
CD5 positive
|
Marginal Zone Lymphoma
|
rituximab Resistant: C3 – Early Trials
|
rituximab Resistant: C3 – Early Trials
|
LDH elevation
|
Marginal Zone Lymphoma
|
LDH elevation
|
Marginal Zone Lymphoma
|
ViPOR Sensitive: C3 – Early Trials
|
ViPOR Sensitive: C3 – Early Trials
|
TP53 mutation + MET amplification + PD-L1 overexpression
|
Marginal Zone Lymphoma
|
TP53 mutation + MET amplification + PD-L1 overexpression
|
Marginal Zone Lymphoma
|
sintilimab Sensitive: C4 – Case Studies
|
sintilimab Sensitive: C4 – Case Studies
|
NOTCH2 mutation + NCOA4 mutation + PTEN mutation + EPHA3 mutation + KMT2D mutation
|
Marginal Zone Lymphoma
|
NOTCH2 mutation + NCOA4 mutation + PTEN mutation + EPHA3 mutation + KMT2D mutation
|
Marginal Zone Lymphoma
|
rituximab Sensitive: C4 – Case Studies
|
rituximab Sensitive: C4 – Case Studies
|
BIRC3-MALT1 fusion
|
Marginal Zone Lymphoma
|
BIRC3-MALT1 fusion
|
Marginal Zone Lymphoma
|
R-CHOP Sensitive: C4 – Case Studies
|
R-CHOP Sensitive: C4 – Case Studies
|
CD20 expression + PAX5 expression + BCL2 expression
|
Marginal Zone Lymphoma
|
CD20 expression + PAX5 expression + BCL2 expression
|
Marginal Zone Lymphoma
|
rituximab Sensitive: C4 – Case Studies
|
rituximab Sensitive: C4 – Case Studies
|